Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
IPO Year: 2021
Exchange: NASDAQ
Website: graphitebio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/23/2023 | $3.00 → $2.00 | Neutral → Underperform | BofA Securities |
| 2/23/2023 | $3.00 | Overweight → Neutral | Cantor Fitzgerald |
| 2/23/2023 | Outperform → Market Perform | Cowen | |
| 1/25/2023 | Buy → Neutral | BTIG Research | |
| 1/18/2023 | $7.00 → $3.00 | Buy → Neutral | BofA Securities |
| 1/6/2023 | $11.00 → $2.00 | Outperform → Mkt Perform | SVB Leerink |
| 1/6/2023 | $14.00 → $7.00 | Outperform → Market Perform | BMO Capital Markets |
| 9/15/2022 | $12.00 | Overweight | Cantor Fitzgerald |
| 6/17/2022 | $12.00 | Outperform | BMO Capital Markets |
| 4/14/2022 | $18.00 | Buy | BTIG Research |
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)
SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)
SC 13D - LENZ Therapeutics, Inc. (0001815776) (Subject)
SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)
SC 13D/A - LENZ Therapeutics, Inc. (0001815776) (Subject)
SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)
SC 13G - Graphite Bio, Inc. (0001815776) (Subject)
SC 13G/A - Graphite Bio, Inc. (0001815776) (Subject)
SC 13D/A - Graphite Bio, Inc. (0001815776) (Subject)
SC 13G/A - Graphite Bio, Inc. (0001815776) (Subject)
Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Graphite Bio, Inc. (NASDAQ:GRPH) ("Graphite" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Lenz Therapeutics, Inc. ("LENZ") pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.03 per share of Graphite's common stock, will be payable in cash to the stockholders of record as of March 18, 2024. The exact amount of the special dividend will be calculated afte
- Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics' lead assets for the treatment of presbyopia - Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5 million from a concurrent PIPE financing - Companies to host joint webcast today, November 15, 2023 at 8:00 a.m. ET LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ:GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock tran
Healthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2023. THIRD QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0% – Third quarter new and renewal lease executions totaled 2.3 million square feet: • Outpatient Medical new and renewal lease executions totaled 2.1 million square feet, an all-time quarterly high, including a 1.3 millio
Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Graphite Bio, Inc. (NASDAQ:GRPH) ("Graphite" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Lenz Therapeutics, Inc. ("LENZ") pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.03 per share of Graphite's common stock, will be payable in cash to the stockholders of record as of March 18, 2024. The exact amount of the special dividend will be calculated afte
- Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics' lead assets for the treatment of presbyopia - Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5 million from a concurrent PIPE financing - Companies to host joint webcast today, November 15, 2023 at 8:00 a.m. ET LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ:GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock tran
Healthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2023. THIRD QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0% – Third quarter new and renewal lease executions totaled 2.3 million square feet: • Outpatient Medical new and renewal lease executions totaled 2.1 million square feet, an all-time quarterly high, including a 1.3 millio
Graphite Bio, Inc. (NASDAQ:GRPH) today announced that Alethia Young, the Company's Chief Financial Officer, will step down from her position to pursue other opportunities. Ms. Young will remain with the Company through June 30, 2023 to oversee her current responsibilities and ensure an orderly transition. "On behalf of the Board and the team at Graphite Bio, I would like to thank Alethia for her dedication and support. She has been an integral part of helping to lead the company since joining us last year. We wish her all the best in her next endeavors," said Josh Lehrer, M.D., M. Phil., Chief Executive Officer of Graphite Bio. "It has been an honor to serve as the first CFO of Graphite B
Graphite Bio, Inc. (NASDAQ:GRPH) today reported recent business progress and fourth quarter and fiscal year 2022 financial results. "As announced last month, Graphite Bio has initiated a process to evaluate strategic alternatives that may result in changes to our business strategy," said CEO Josh Lehrer, M.D., M.Phil. "We are working expeditiously to complete this strategic review and look forward to providing an update in the future when appropriate." Recent Business Updates In February 2023, Graphite Bio announced its decision to discontinue development of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease and initiate a process to explore strategic alternatives. As a resu
Graphite Bio, Inc. (NASDAQ:GRPH) today announced that it has completed a review of its business, including the status of its programs, resources and capabilities. The company has decided to discontinue further development of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease and to initiate a process to explore a range of strategic alternatives. "We believe that gene correction is the optimal way to treat sickle cell and many other genetic diseases. However, after an extensive assessment of the nula-cel program, we made the difficult decision to discontinue nula-cel development based on the time and resources needed to resume the CEDAR study and the evolving treatment landscape
Graphite Bio, Inc. (NASDAQ:GRPH) today announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) due to a serious adverse event in the first patient dosed with nula-cel, and the company's conclusion that the event is likely related to study treatment. As a result, the company will not meet its guidance for initial proof-of-concept data in mid-2023. The decision by Graphite Bio to voluntarily pause the CEDAR study follows a serious and unexpected adverse event of prolonged low blood cell counts (pancytopenia) requiring ongoing transfusion and growth factor support in the first patient dosed with nula-cel. The event
Single-cell RNA sequencing of reticulocytes will be used to measure gene correction outcomes in sickle cell patients treated with nulabeglogene autogedtemcel (nula-cel) Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today presented preclinical results supporting the use of a single-cell RNA sequencing method to assess gene correction outcomes in patients treated with nulabeglogene autogedtemcel (nula-cel), an investigational gene-edited therapy for sickle cell disease (SCD). The findings are being presented in a p
Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Thursday, Dec. 1, 2022, at 11:45 a.m. ET. The fireside chat will be webcast live from Graphite Bio's website at www.graphitebio.com in the Investors section. A replay of the webcast will be archived and available following the event. About Graphite Bio Graphite Bio is a clinical-stage, next-generation gene editing company dr
Dosed first sickle cell patient with nula-cel; initial proof-of-concept data on track for mid-2023 Two abstracts accepted for 64th ASH Annual Meeting and Exposition in December Entered strategic partnership with Philadelphia-based WuXi Advanced Therapies for the manufacturing of nula-cel Bolstered company leadership with hiring of senior vice president of development $305.1 million in cash, cash equivalents and investments in marketable securities as of September 30, 2022; cash runway into fourth quarter 2024 Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with th
Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the appointment of Alethia Young as chief financial officer. Ms. Young joins Graphite Bio from Cantor Fitzgerald, where she served as senior biotech analyst and head of research, managing the equity research department covering small-cap, mid-cap and large-cap biotechnology companies. In this newly created position, Ms. Young will oversee the company's finance, investor relations and corporate communications functions, and will play a key role in overall corporate strategy. "On behalf of the e
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
3 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
3 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
3 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
424B3 - LENZ Therapeutics, Inc. (0001815776) (Filer)
10-Q - LENZ Therapeutics, Inc. (0001815776) (Filer)
8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)
EFFECT - LENZ Therapeutics, Inc. (0001815776) (Filer)
424B3 - LENZ Therapeutics, Inc. (0001815776) (Filer)
8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)
S-1 - LENZ Therapeutics, Inc. (0001815776) (Filer)
8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)
8-K - Graphite Bio, Inc. (0001815776) (Filer)
8-K - Graphite Bio, Inc. (0001815776) (Filer)
BofA Securities downgraded Graphite Bio from Neutral to Underperform and set a new price target of $2.00 from $3.00 previously
Cantor Fitzgerald downgraded Graphite Bio from Overweight to Neutral and set a new price target of $3.00
Cowen downgraded Graphite Bio from Outperform to Market Perform
BTIG Research downgraded Graphite Bio from Buy to Neutral
BofA Securities downgraded Graphite Bio from Buy to Neutral and set a new price target of $3.00 from $7.00 previously
SVB Leerink downgraded Graphite Bio from Outperform to Mkt Perform and set a new price target of $2.00 from $11.00 previously
BMO Capital Markets downgraded Graphite Bio from Outperform to Market Perform and set a new price target of $7.00 from $14.00 previously
Cantor Fitzgerald initiated coverage of Graphite Bio with a rating of Overweight and set a new price target of $12.00
BMO Capital Markets initiated coverage of Graphite Bio with a rating of Outperform and set a new price target of $12.00
BTIG Research initiated coverage of Graphite Bio with a rating of Buy and set a new price target of $18.00